MCQ Hematology Answer 30

The Correct Answer is : C


Explanation:

Anagrelide is an oral imidazoquinazolin derivative that has been approved by the FDA as a platelet-lowering agent in essential thrombocythemia. It appears to lower the platelet count by interfering with the maturation of megakaryocytes. There are some side effects, but they are relatively mild in most cases. It should not be administered in cases of reactive thrombocytosis because their risk of complications from thrombocytosis is much less than in patients with thrombocytosis from inherent marrow disorder.

Because essential thrombocytosis patients are at risk for hemorrhage as well as thrombosis, aspirin is not indicated in all cases.

Hydroxyurea has a potential leukemogenic risk because it is a chemotherapeutic, although this risk has not been substantiated. Anagrelide lacks this potential risk because it is not a chemotherapeutic agent.

Interferon has many more associated side effects with less efficacy. Thus, anagrelide appears to offer the best therapeutic window with the fewest risks and is the treatment of choice for essential thrombocythemia as long as it is tolerated by the patient.

Category: Hematology MCQs